A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Vismodegib (Primary)
- Indications Medulloblastoma
- Focus Adverse reactions; Pharmacokinetics
- 05 Mar 2012 Actual patient number changed from 13 to 21 as reported by ClinicalTrials.gov.
- 22 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 06 Jun 2010 Status changed from recruiting to completed, based on information reported in a St. Jude Children's Research Hospital media release.